CN103402543B - 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法 - Google Patents

用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法 Download PDF

Info

Publication number
CN103402543B
CN103402543B CN201180067824.5A CN201180067824A CN103402543B CN 103402543 B CN103402543 B CN 103402543B CN 201180067824 A CN201180067824 A CN 201180067824A CN 103402543 B CN103402543 B CN 103402543B
Authority
CN
China
Prior art keywords
composition
solvent
itza
peg
azole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180067824.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103402543A (zh
Inventor
伯耶·S·安德森
杰弗里·塔兰德
贝尼尼奥·C·瓦尔德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Second Pulafumu Hardware Co Ltd
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN103402543A publication Critical patent/CN103402543A/zh
Application granted granted Critical
Publication of CN103402543B publication Critical patent/CN103402543B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180067824.5A 2010-12-16 2011-12-16 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法 Expired - Fee Related CN103402543B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42393710P 2010-12-16 2010-12-16
US61/423,937 2010-12-16
US201161509154P 2011-07-19 2011-07-19
US61/509,154 2011-07-19
PCT/US2011/065422 WO2012083138A2 (en) 2010-12-16 2011-12-16 Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds

Publications (2)

Publication Number Publication Date
CN103402543A CN103402543A (zh) 2013-11-20
CN103402543B true CN103402543B (zh) 2015-09-16

Family

ID=46245384

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180067824.5A Expired - Fee Related CN103402543B (zh) 2010-12-16 2011-12-16 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法

Country Status (15)

Country Link
US (2) US10307418B2 (enExample)
EP (1) EP2651450B1 (enExample)
JP (2) JP6086539B2 (enExample)
CN (1) CN103402543B (enExample)
AU (1) AU2011343576B2 (enExample)
BR (1) BR112013015085A8 (enExample)
CA (1) CA2821823C (enExample)
DK (1) DK2651450T3 (enExample)
ES (1) ES2565353T3 (enExample)
HU (1) HUE028667T2 (enExample)
IL (1) IL226977A (enExample)
MX (1) MX337364B (enExample)
NZ (1) NZ613167A (enExample)
RU (2) RU2618456C2 (enExample)
WO (1) WO2012083138A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ613167A (en) * 2010-12-16 2015-09-25 Univ Texas Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
ES2822350T3 (es) * 2011-04-28 2021-04-30 Platform Brightworks Two Ltd Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas
SG11201504976UA (en) * 2012-12-28 2015-07-30 Suntory Holdings Ltd Non-alcohol, beer-taste beverage having shimari in taste
CN105394045B (zh) * 2014-09-04 2020-02-14 中国科学院上海巴斯德研究所 一种肠道病毒的小分子化合物抑制剂及其应用
CN105943500B (zh) * 2016-07-08 2019-01-04 河南省立眼科医院 一种含有艾沙康唑的眼用纳米胶束抗真菌溶液
TWI834808B (zh) 2019-02-19 2024-03-11 西班牙商薩爾瓦特實驗室有限公司 以單劑包裝的克氯黴唑液體組成物
CN111665301A (zh) * 2020-05-29 2020-09-15 南京品生医疗科技有限公司 超高效液相色谱串联质谱技术检测血清中抗真菌药物的试剂盒
CN116507319A (zh) * 2020-11-16 2023-07-28 W.L.戈尔及同仁股份有限公司 不含浊点的制剂、方法和预填充多剂量注射装置
CN113671086B (zh) * 2021-08-31 2023-06-16 重庆华邦制药有限公司 分离、测定泊沙康唑z2及其杂质的方法
CN114660200A (zh) * 2022-03-29 2022-06-24 中国人民解放军总医院 一种高效液相色谱串联质谱技术同时测定血浆中4种三唑类抗真菌药物的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912124A (en) * 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
DE3702105A1 (de) 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
JPH01242525A (ja) 1988-03-25 1989-09-27 Nippon Nohyaku Co Ltd 抗真菌外用剤
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
KR0159730B1 (ko) * 1996-01-15 1998-12-01 손경식 케토코나졸 수성 제제
US7179475B1 (en) * 1998-12-04 2007-02-20 Johnson & Johnson Consumer Companies, Inc. Anhydrous topical skin preparations
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
GB2365770B (en) 2000-08-18 2002-07-31 Diomed Dev Ltd Antifungal ketoconazole composition for topical use
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
JP2002322056A (ja) 2001-04-27 2002-11-08 Nippon Kayaku Co Ltd トリアゾール誘導体の溶液製剤
JP4263441B2 (ja) * 2002-08-07 2009-05-13 富士重工業株式会社 ４輪駆動車の制御装置
WO2004014431A1 (en) 2002-08-12 2004-02-19 Ranbaxy Laboratories Limited A parenteral dosage form of selective cox-2 inhibitors
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US20060003654A1 (en) * 2004-06-30 2006-01-05 Lostocco Michael R Dispersible alcohol/cleaning wipes via topical or wet-end application of acrylamide or vinylamide/amine polymers
WO2006105399A1 (en) 2005-03-31 2006-10-05 Bristol-Myers Squibb Company Methods for administering ixabepilone
CA2613389A1 (en) 2005-06-27 2007-01-04 Barrier Therapeutics, Inc. Micogel topical formulations
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AU2007355106A1 (en) * 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
KR20100075475A (ko) 2007-09-05 2010-07-02 가부시키가이샤 폴라 파마 의약 조성물
US20090253712A1 (en) 2008-04-03 2009-10-08 Semmelweis Egyetem Aqueous solvent system for solubilization of azole compounds
WO2009139925A1 (en) * 2008-05-16 2009-11-19 Panacea Pharmaceuticals, Inc. Methods for the treatment of brain edema
MX2011008204A (es) 2009-02-05 2011-12-06 Targeted Delivery Technologies Ltd Metodos para reducir la proliferacion y viabilidad de los agentes microbianos.
CN102387785B (zh) 2009-04-09 2017-08-25 宝丽制药股份有限公司 抗真菌药物组合物
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
NZ613167A (en) * 2010-12-16 2015-09-25 Univ Texas Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
ES2822350T3 (es) * 2011-04-28 2021-04-30 Platform Brightworks Two Ltd Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas

Also Published As

Publication number Publication date
RU2016149770A3 (enExample) 2020-02-04
JP6086539B2 (ja) 2017-03-01
JP2013545819A (ja) 2013-12-26
RU2734128C2 (ru) 2020-10-13
IL226977A (en) 2017-01-31
RU2618456C2 (ru) 2017-05-03
CN103402543A (zh) 2013-11-20
ES2565353T3 (es) 2016-04-04
MX337364B (es) 2016-02-29
HK1190643A1 (zh) 2014-07-11
US20140031366A1 (en) 2014-01-30
CA2821823C (en) 2019-05-07
NZ613167A (en) 2015-09-25
BR112013015085A8 (pt) 2018-04-03
BR112013015085A2 (pt) 2016-08-09
RU2013132703A (ru) 2015-01-27
US20190240216A1 (en) 2019-08-08
WO2012083138A2 (en) 2012-06-21
HUE028667T2 (en) 2016-12-28
EP2651450A2 (en) 2013-10-23
EP2651450A4 (en) 2014-07-09
DK2651450T3 (en) 2016-03-14
WO2012083138A3 (en) 2012-11-01
RU2016149770A (ru) 2018-11-05
JP2017114869A (ja) 2017-06-29
AU2011343576A1 (en) 2013-07-11
JP6529527B2 (ja) 2019-06-12
MX2013006816A (es) 2013-11-01
CA2821823A1 (en) 2012-06-21
AU2011343576B2 (en) 2016-09-08
EP2651450B1 (en) 2015-12-16
US10307418B2 (en) 2019-06-04

Similar Documents

Publication Publication Date Title
CN103402543B (zh) 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法
US20220265829A1 (en) Formulations of bendamustine
JP6008849B2 (ja) 置換β−シクロデキストリンにより安定化されたポサコナゾール静脈注射用溶液製剤
KR101502533B1 (ko) 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
KR100800503B1 (ko) 항진균 비경구 제품
CN102421451A (zh) 苯达莫司汀环多糖组合物
Mehta et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study
JP2016534062A (ja) 新規な安定製剤
AU2011302885B2 (en) Non-aqueous oily injectable formulation exhibiting preservative efficacy
HK1190643B (en) Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
US20030082229A1 (en) Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
WO2019094819A2 (en) Intravenous delivery systems for chemotherapy drugs
EP3220954A2 (en) Process for preparation of parenteral formulation of anidulafungin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1190643

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20151207

Address after: Texas, USA

Patentee after: Beyer S. Anderson

Patentee after: Tarrand Jeffery

Patentee after: Benigno C.Valdes

Address before: Austen, Texas, USA

Patentee before: Board of Regents, The University of Texas System

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1190643

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20170213

Address after: American Texas

Patentee after: Second Pulafumu Hardware Co. Ltd.

Address before: American Texas

Patentee before: Beyer S. Anderson

Patentee before: Tarrand Jeffery

Patentee before: Benigno C. Walders

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150916

Termination date: 20201216

CF01 Termination of patent right due to non-payment of annual fee